A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation

R. A. Clift, J. A. Bianco, F. R. Appelbaum, C. D. Buckner, J. W. Singer, L. Bakke, W. I. Bensinger, R. A. Bowden, G. B. McDonald, M. Schubert, A. F. Shields, J. T. Slattery, R. Storb, L. D. Fisher, Motomi (Tomi) Mori, E. D. Thomas, J. A. Hansen

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

This study evaluated the effect of pentoxifylline (PTX) on the incidence of regimen-related toxicity in patients receiving allogeneic marrow transplants from rejated donors. All patients received a regimen of methotrexate and cyclosporine as prophylaxis against acute graft-versus-host disease (GVHD). Patients were randomized to receive PTX or a placebo for 70 days and the outcome was examined in a blinded fashion. Forty-four patients were evaluable in each study arm. PTX had no significant effect on engraftment, the incidence of GVHD, venocclusive disease of the liver. infection, the need for oxygen, posttransplant survival, or the duration of hospitalization. Patients receiving PTX were significantly more likely to develop major elevations of serum creatinine levels. PTX was poorly tolerated and induced significantly more vomiting than the placebo. PTX as administered in this randomized study was associated with significant toxicity and offered no benefit in reducing transplant-related morbidity or mortality.

Original languageEnglish (US)
Pages (from-to)2025-2030
Number of pages6
JournalBlood
Volume82
Issue number7
StatePublished - Oct 1 1993
Externally publishedYes

Fingerprint

Pentoxifylline
Homologous Transplantation
Toxicity
Randomized Controlled Trials
Bone Marrow
Transplants
Graft vs Host Disease
Grafts
Placebos
Incidence
Methotrexate
Liver
Cyclosporine
Vomiting
Liver Diseases
Creatinine
Hospitalization
Arm
Tissue Donors
Oxygen

ASJC Scopus subject areas

  • Hematology

Cite this

Clift, R. A., Bianco, J. A., Appelbaum, F. R., Buckner, C. D., Singer, J. W., Bakke, L., ... Hansen, J. A. (1993). A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood, 82(7), 2025-2030.

A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. / Clift, R. A.; Bianco, J. A.; Appelbaum, F. R.; Buckner, C. D.; Singer, J. W.; Bakke, L.; Bensinger, W. I.; Bowden, R. A.; McDonald, G. B.; Schubert, M.; Shields, A. F.; Slattery, J. T.; Storb, R.; Fisher, L. D.; Mori, Motomi (Tomi); Thomas, E. D.; Hansen, J. A.

In: Blood, Vol. 82, No. 7, 01.10.1993, p. 2025-2030.

Research output: Contribution to journalArticle

Clift, RA, Bianco, JA, Appelbaum, FR, Buckner, CD, Singer, JW, Bakke, L, Bensinger, WI, Bowden, RA, McDonald, GB, Schubert, M, Shields, AF, Slattery, JT, Storb, R, Fisher, LD, Mori, MT, Thomas, ED & Hansen, JA 1993, 'A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation', Blood, vol. 82, no. 7, pp. 2025-2030.
Clift, R. A. ; Bianco, J. A. ; Appelbaum, F. R. ; Buckner, C. D. ; Singer, J. W. ; Bakke, L. ; Bensinger, W. I. ; Bowden, R. A. ; McDonald, G. B. ; Schubert, M. ; Shields, A. F. ; Slattery, J. T. ; Storb, R. ; Fisher, L. D. ; Mori, Motomi (Tomi) ; Thomas, E. D. ; Hansen, J. A. / A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. In: Blood. 1993 ; Vol. 82, No. 7. pp. 2025-2030.
@article{13710c418343461ba8a47b1b8d988640,
title = "A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation",
abstract = "This study evaluated the effect of pentoxifylline (PTX) on the incidence of regimen-related toxicity in patients receiving allogeneic marrow transplants from rejated donors. All patients received a regimen of methotrexate and cyclosporine as prophylaxis against acute graft-versus-host disease (GVHD). Patients were randomized to receive PTX or a placebo for 70 days and the outcome was examined in a blinded fashion. Forty-four patients were evaluable in each study arm. PTX had no significant effect on engraftment, the incidence of GVHD, venocclusive disease of the liver. infection, the need for oxygen, posttransplant survival, or the duration of hospitalization. Patients receiving PTX were significantly more likely to develop major elevations of serum creatinine levels. PTX was poorly tolerated and induced significantly more vomiting than the placebo. PTX as administered in this randomized study was associated with significant toxicity and offered no benefit in reducing transplant-related morbidity or mortality.",
author = "Clift, {R. A.} and Bianco, {J. A.} and Appelbaum, {F. R.} and Buckner, {C. D.} and Singer, {J. W.} and L. Bakke and Bensinger, {W. I.} and Bowden, {R. A.} and McDonald, {G. B.} and M. Schubert and Shields, {A. F.} and Slattery, {J. T.} and R. Storb and Fisher, {L. D.} and Mori, {Motomi (Tomi)} and Thomas, {E. D.} and Hansen, {J. A.}",
year = "1993",
month = "10",
day = "1",
language = "English (US)",
volume = "82",
pages = "2025--2030",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation

AU - Clift, R. A.

AU - Bianco, J. A.

AU - Appelbaum, F. R.

AU - Buckner, C. D.

AU - Singer, J. W.

AU - Bakke, L.

AU - Bensinger, W. I.

AU - Bowden, R. A.

AU - McDonald, G. B.

AU - Schubert, M.

AU - Shields, A. F.

AU - Slattery, J. T.

AU - Storb, R.

AU - Fisher, L. D.

AU - Mori, Motomi (Tomi)

AU - Thomas, E. D.

AU - Hansen, J. A.

PY - 1993/10/1

Y1 - 1993/10/1

N2 - This study evaluated the effect of pentoxifylline (PTX) on the incidence of regimen-related toxicity in patients receiving allogeneic marrow transplants from rejated donors. All patients received a regimen of methotrexate and cyclosporine as prophylaxis against acute graft-versus-host disease (GVHD). Patients were randomized to receive PTX or a placebo for 70 days and the outcome was examined in a blinded fashion. Forty-four patients were evaluable in each study arm. PTX had no significant effect on engraftment, the incidence of GVHD, venocclusive disease of the liver. infection, the need for oxygen, posttransplant survival, or the duration of hospitalization. Patients receiving PTX were significantly more likely to develop major elevations of serum creatinine levels. PTX was poorly tolerated and induced significantly more vomiting than the placebo. PTX as administered in this randomized study was associated with significant toxicity and offered no benefit in reducing transplant-related morbidity or mortality.

AB - This study evaluated the effect of pentoxifylline (PTX) on the incidence of regimen-related toxicity in patients receiving allogeneic marrow transplants from rejated donors. All patients received a regimen of methotrexate and cyclosporine as prophylaxis against acute graft-versus-host disease (GVHD). Patients were randomized to receive PTX or a placebo for 70 days and the outcome was examined in a blinded fashion. Forty-four patients were evaluable in each study arm. PTX had no significant effect on engraftment, the incidence of GVHD, venocclusive disease of the liver. infection, the need for oxygen, posttransplant survival, or the duration of hospitalization. Patients receiving PTX were significantly more likely to develop major elevations of serum creatinine levels. PTX was poorly tolerated and induced significantly more vomiting than the placebo. PTX as administered in this randomized study was associated with significant toxicity and offered no benefit in reducing transplant-related morbidity or mortality.

UR - http://www.scopus.com/inward/record.url?scp=0027358515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027358515&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 2025

EP - 2030

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -